This article aims at presenting an emerging, yeast-related, health threat. Candida auris (Metschnikowiaceae, andida/Clavispora clade), is an emerging fungus, that presents a serious global health threat. It causes wounds, ears, respiratory and urinary tracts infections. In some patients, these yeasts can enter the bloodstream and spread throughout the body, causing serious systemic infections. C.auris is often resistant to commonly used antifungal drugs, such as amphotericin B, polyenes or echinocandins, making infections difficult to treat. C. auris persists in the environment for months, and nersistent environmental contamination, contaminated medical equipment and other fomites, are believed to play a role in nosocomial C. auris transmission. Specialized laboratory methods (RT-PCR, MALDI-TOF MS), are needed to accurately identify C. auris yeast. Echinocandins are currently recommended as first-line therapy in adults and in infants (children above 2 months of age). For neonates amphotericin B deoxycholate is recommended. It is suspected, that C. auris may also be pathogenic to animals.